Acquisition of Reliant Pharma

GlaxoSmithKline PLC
21 November 2007

                     GSK to Acquire Reliant Pharmaceuticals



        Addition of Lovaza to expand GSK cardiovascular portfolio in US

                  Acquisition provides sales, synergy benefits



London, UK, Philadelphia, PA, and Liberty Corner, NJ (November 21, 2007) -
GlaxoSmithKline (LSE & NYSE: GSK) and Reliant Pharmaceuticals Inc. announced
today that they had reached an agreement under which Reliant will be acquired by
GSK for $1.65 billion (£800 million) in cash.



Reliant, a privately held specialty pharmaceutical company focused on
cardiovascular therapies, recorded net sales of $341 million in the nine months
ending September 30, 2007, an increase of 62% over the comparable time period a
year earlier.



GSK expects the transaction will be slightly accretive to earnings in 2008,
excluding integration costs, and will create additional value in following
years.



Through its strategic in-licensing and development strategy, Reliant has
developed a portfolio of specialty medicines combating heart disease, including
US rights to LovazaTM (omega-3-acid ethyl esters), a treatment for adult
patients with very high levels of triglycerides.  Triglycerides are fatty
substances in the blood associated with increased risks of coronary artery
disease.  Lovaza is indicated as an adjunct to diet to reduce triglyceride
levels in adults with very high ((3)500 mg/dL) triglyceride levels.



High lipid levels continue to be a growing health problem in the United States,
with up to 5 million people having triglyceride levels classified as very high.
Lovaza is the only prescription omega-3 medicine approved by the US Food and
Drug Administration for the treatment of very high triglycerides, and remains
the only omega-3 medicine that, along with diet and exercise, has been
clinically proven to provide a 45% reduction in triglycerides in adult patients
with very high triglyceride levels.



Launched in late 2005, Lovaza (formerly known as Omacor(R)) achieved rapid
uptake among patients and health care professionals.  In the nine months ending
September 30, 2007, net sales were $206 million, an increase of 115% over the
first nine months of 2006.



Lovaza competes in the non-statin dyslipidemia segment of the US cardiovascular
market, where it had achieved a 10% market share of total prescriptions as of
September 30, 2007.  Sales in the non-statin dyslipidemia market totaled
approximately $2.2 billion in 2006 and are expected to grow in excess of 20% a
year.  GSK believes there is significant opportunity for future growth of Lovaza
in this market segment.



Reliant licensed the rights to Lovaza in the US and Puerto Rico from Pronova
BioPharma ASA (Oslo: PRON), a publicly traded Norwegian company that will
continue to supply the product's primary material.  Rights to Lovaza in other
markets have been licensed by Pronova to several other companies.



Commenting on the acquisition agreement, Chris Viehbacher, President, US
Pharmaceuticals, GSK, said, "The addition of Lovaza to the GSK portfolio adds a
new driver of sales growth in the US business.  It represents a strong strategic
fit, complementing Coreg CR(R), a leading treatment for heart failure and
hypertension, and adds to our growing profile in the cardiovascular disease
area."



"Today is a momentous date for Reliant," said Bradley T. Sheares, CEO of
Reliant.  "We are very proud of the work that our employees have done to build
this company, particularly the energy and perseverance of our sales teams, who
have demonstrated their worth in building a formidable Lovaza franchise in less
than 24 months.  We see great additional potential through this acquisition for
Lovaza and the patients who could benefit from it."


The acquisition is subject to approval by the US Federal Trade Commission and is
expected to conclude before year-end.



In addition to Lovaza, Reliant Pharmaceuticals, based in Liberty Corner, NJ,
currently markets three other in-licensed cardiovascular products - high blood
pressure treatments DynaCirc CR(R) (isradipine) and InnoPran XL(R) (propanolol
HCl), as well as Rythmol SR(R) (propafenone), which treats abnormal heart
rhythms, or arrhythmia.



S M Bicknell

Company Secretary



21st November 2007





About GSK

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.  For company
information, visit www.gsk.com.



GlaxoSmithKline forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995, GSK cautions investors that any forward-looking statements
or projections made by GSK, including those made in this announcement, are
subject to risks and uncertainties that may cause actual results to differ
materially from those projected.  Factors that may affect GSK's operations are
described under 'Risk Factors' in the Operating and Financial Review and
Prospects in the company's Annual Report on Form 20-F for 2006.



About Reliant Pharmaceuticals

Reliant Pharmaceuticals, Inc. is a pharmaceutical company that specializes in
the development, commercialization and marketing of prescription therapeutic
products.  Reliant currently markets four cardiovascular products in the United
States and focuses on promoting its products to targeted primary care and
specialty physicians, as well as selected hospitals and academic centers in the
United States.  Reliant's sales force infrastructure is comprised of
approximately 880 sales and marketing professionals nationwide.



Reliant Pharmaceuticals forward-looking statements

To the extent any statements made in this release contain information that is
not historical, these statements are essentially forward looking and are subject
to risks and uncertainties, and other factors that may cause Reliant's actual
results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or
achievements expressed or implied by these forward-looking statements.  You
should not place undue reliance on forward-looking statements since they involve
known and unknown risks, uncertainties and other factors which are, in some
cases, beyond Reliant's control and which could materially affect actual
results, levels of activity, performance or achievements.







GlaxoSmithKline inquiries:

US media inquiries:                            Rick Sluder      [phone]


UK media inquiries:                            Philip Thomson   [phone]
                                               Alice Hunt       [phone]
                                               Joss Mathieson   [phone]
                                               Claire Brough    [phone]



US analyst/investor inquiries:                 Frank Murdolo    [phone]
                                               Tom Curry        [phone]



European analyst/investor inquiries:           David Mawdsley   [phone]
                                               Sally Ferguson   [phone]



Reliant inquiries:                             Marylou Rowe     [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange